REDDSTAR

Repair of Diabetic Damage by Stromal Cell Administration

 Coordinatore NATIONAL UNIVERSITY OF IRELAND, GALWAY 

 Organization address address: University Road -
city: GALWAY

contact info
Titolo: Ms.
Nome: Mari
Cognome: Vahey
Email: send email
Telefono: +353 91 495939

 Nazionalità Coordinatore Ireland [IE]
 Sito del progetto http://www.reddstar.eu/
 Totale costo 8˙240˙280 €
 EC contributo 5˙894˙387 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-11-01   -   2015-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND, GALWAY

 Organization address address: University Road -
city: GALWAY

contact info
Titolo: Ms.
Nome: Mari
Cognome: Vahey
Email: send email
Telefono: +353 91 495939

IE (GALWAY) coordinator 1˙073˙192.00
2    ORBSEN THERAPEUTICS LIMITED

 Organization address address: ORBSEN BUILDING NATIONAL UNIVERSITY OF IRELAND
city: GALWAY

contact info
Titolo: Dr.
Nome: Stephen Joseph
Cognome: Elliman
Email: send email
Telefono: 353877000000

IE (GALWAY) participant 986˙896.00
3    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: +49 30 450576024

DE (BERLIN) participant 575˙700.00
4    OWL BIOMEDICAL INC

 Organization address address: ROBIN HILL ROAD 75
city: GOLETA
postcode: 93117

contact info
Titolo: Dr.
Nome: John
Cognome: Foster
Email: send email
Telefono: 18054520181

US (GOLETA) participant 552˙909.00
5    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Dr.
Nome: Brigitte
Cognome: Wieles
Email: send email
Telefono: 31715263413

NL (LEIDEN) participant 552˙200.00
6    QUEEN'S UNIVERSITY BELFAST

 Organization address address: University Road
city: BELFAST
postcode: BT7 1NN

contact info
Titolo: Ms.
Nome: Colleen
Cognome: Spence
Email: send email
Telefono: +44 28 9097 5183
Fax: +44 28 9097 5182

UK (BELFAST) participant 550˙523.00
7    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Prof.
Nome: Hans-Joachim
Cognome: Anders
Email: send email
Telefono: 498952000000
Fax: 498952000000

DE (MUENCHEN) participant 536˙680.00
8    Steno Diabetes Center A/S

 Organization address address: Niels Steensens Vej 2
city: Gentofte
postcode: 2820

contact info
Titolo: Ms.
Nome: Michelle
Cognome: Ellefson
Email: send email
Telefono: +45 4442 8296

DK (Gentofte) participant 534˙040.00
9    UNIVERSIDADE DO PORTO

 Organization address address: PRACA GOMES TEIXEIRA
city: PORTO
postcode: 4099 002

contact info
Titolo: Dr.
Nome: Manuela
Cognome: Mota
Email: send email
Telefono: +351 225 513 608
Fax: +351 225 513 601

PT (PORTO) participant 301˙747.00
10    PINTAIL LTD

 Organization address address: SPRINGHILL AVENUE 77
city: BLACKROCK

contact info
Titolo: Mr.
Nome: Kay
Cognome: Clissmann
Email: send email
Telefono: +353 1 2899529

IE (BLACKROCK) participant 230˙500.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

agents    msc    marrow    glycaemia    first    medicines    patients    retinopathy    cardiomyopathy    tissue    wound    million    models    pa    healing    repair    ssc    bone    pre    neuropathy    administration    mixed    human    mouse    mscs    adult    antibody    clinical    reddstar    distinct    glucose    stem    model    leads    species    potent    stromal    approved    immunosuppressive    damage    nephropathy    levels    diabetes    cells    complications       trials    therapy    secrete    cell    angiogenic    hyperglycaemia    anti    diabetic    safety   

 Obiettivo del progetto (Objective)

'50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control leads to 6 progressive diabetic complications, namely: nephropathy, retinopathy, cardiomyopathy, neuropathy and foot ulceration. In 2010, 11% of EU adult deaths (634,000) were caused by diabetic complications. These distinct disorders have few effective medicines and present challenging management issues for clinicians. Stromal Stem Cells (SSC) are a mixed population of plastic-adherent (PA) cells isolated from adult bone marrow. PA-SSC secrete potent immunosuppressive and angiogenic proteins and over 100 clinical trials are testing PA-SSC in 40 distinct autoimmune and ischemic diseases. Notably, preclinical studies show a single intravenous administration of un-modified PA-SSC can control rodent hyperglycaemia, prompting 10 recent clinical safety studies in diabetic patients. REDDSTAR will comprehensively examine if SSC can safely repair all 6 damaged tissues and control glycaemia in three different species. To facilitate this we identified an antibody (S2) that prospectively isolates comparable, equivalent S2SSC from human, rat, mouse and rabbit marrow, enabling testing of pure S2/- SSC and mixed PA-SSC from each species for the first time. Furthermore, separation of PA-SSC into S2 and S2- fractions reveal functionally distinct populations. REDDSTAR partners have collectively developed five distinct clinically-relevant in vivo models of the 6 key diabetic complications. We will assess if S2, S2- and PA-SSC exert differing control of glycaemia and tissue repair in each model. Finally, REDDSTAR partners are developing the first benchtop GMP-grade nanosorter, enabling clinical purification of S2 and S2- SSC for human safety trials. We will dissect how S2 and S2- SSC simultaneously repair tissue damage and maintain glycaemic control, an effect not observed with any current therapy.'

Introduzione (Teaser)

Improving the treatments available for diabetic patients and enhancing their health and quality of life represents a major challenge. A European study follows an innovative approach based on mesenchymal stem cells (MSCs) to repair the damage induced by high glucose levels.

Descrizione progetto (Article)

Nearly 50 million people in Europe are using approved anti-diabetic agents to control their high glucose levels. Poorly controlled glucose levels lead to complications such as nephropathy, retinopathy, cardiomyopathy and neuropathy, which can prove fatal in 11% of cases.

The main regimen for diabetes is insulin administration, which slows down the emergence of these complications but often at the expense of hypoglycaemic episodes. As there are no other effective medicines available, glucose control in diabetes remains a key clinical challenge.

Scientists on the EU-funded 'Repair of diabetic damage by stromal cell administration' (http://www.reddstar.eu/ (REDDSTAR)) project propose to treat diabetes and its complications using MSCs. Accumulating evidence indicates that - MSCs or stromal stem cells from adult bone marrow secrete potent immunosuppressive and angiogenic factors. Also, their administration in rodents controls hyperglycaemia.

REDDSTAR's primary objective is to investigate the safety and efficacy of such MSC administration with respect to glucose metabolism control and amelioration of diabetes-related complications. Cell isolation is performed using a novel antibody against the surface marker Syndecan-2, which leads to high purity and complies with clinical regulations.

Researchers administered MSCs in pre-clinical models of diabetes and have observed positive effects on blood glucose, kidney disease, neuropathy and wound healing. MSCs have also improved the retinal vascularisation in a mouse model of diabetic retinopathy, while beneficial immunomodulatory effects have been observed in a mouse model of diabetic cardiomyopathy.

Although still at the pre-clinical level, these promising effects of MSC administration on diabetic complications provide the first step for a potential new therapy for diabetes. The planned clinical trial is expected to validate these observations in diabetic wound healing in humans and bring MSC therapy a step closer to the clinic.

Altri progetti dello stesso programma (FP7-HEALTH)

DEXLIFE (2012)

Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at high-risk for progression

Read More  

PEMPHIGUS (2008)

Pemphigus - From autoimmunity to disease

Read More  

GENODISC (2008)

Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair

Read More